These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33438173)

  • 1. Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG.
    Walsh MC; Choi Y
    J Bone Miner Metab; 2021 Jan; 39(1):54-63. PubMed ID: 33438173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L; Marotta Pdos S; Pires FR; Siqueira JF
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.
    Baud'huin M; Lamoureux F; Duplomb L; Rédini F; Heymann D
    Cell Mol Life Sci; 2007 Sep; 64(18):2334-50. PubMed ID: 17530461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration.
    Sano T; Akeda K; Yamada J; Takegami N; Sudo T; Sudo A
    BMC Musculoskelet Disord; 2019 May; 20(1):225. PubMed ID: 31101043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
    Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
    BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK/RANKL/OPG system in the intervertebral disc.
    Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
    Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
    Vitovski S; Phillips JS; Sayers J; Croucher PI
    J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond.
    Walsh MC; Choi Y
    Front Immunol; 2014; 5():511. PubMed ID: 25368616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL biology.
    Takegahara N; Kim H; Choi Y
    Bone; 2022 Jun; 159():116353. PubMed ID: 35181574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The participation of RANK, RANKL and OPG in tumor osteolysis].
    Stanisławowski M; Kmieć Z
    Postepy Hig Med Dosw (Online); 2009 May; 63():234-41. PubMed ID: 19502684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
    Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
    Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin mediate RANK/RANKL signaling inhibition eases asthma inflammatory reaction by affecting the survival and function of dendritic cells.
    Yang X; Wang X; Chi M; Zhang M; Shan H; Zhang QH; Zhang J; Shi J; Zhang JZ; Wu RM; Li YL
    Allergol Immunopathol (Madr); 2019; 47(2):179-184. PubMed ID: 30292447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of the RANKL/RANK/OPG system.
    Yasuda H
    J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.
    Shimamura M; Nakagami H; Osako MK; Kurinami H; Koriyama H; Zhengda P; Tomioka H; Tenma A; Wakayama K; Morishita R
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8191-6. PubMed ID: 24847069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.